Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.
COVID-19
Lung cancer
Non-small cell lung cancer
Pandemic
Radiotherapy
Small cell lung cancer
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
01
04
2020
accepted:
01
04
2020
pubmed:
29
4
2020
medline:
26
6
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic.
METHODS
For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC.
RESULTS
In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided.
CONCLUSION
This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.
Identifiants
pubmed: 32342863
pii: S0167-8140(20)30182-1
doi: 10.1016/j.radonc.2020.04.001
pmc: PMC7252074
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-229Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Références
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e157-63
pubmed: 23182393
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Oncol (R Coll Radiol). 1996;8(3):167-75
pubmed: 8814371
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
Crit Care Clin. 2019 Oct;35(4):575-589
pubmed: 31445606
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):719-28
pubmed: 12377323
Br J Cancer. 1992 Jun;65(6):934-41
pubmed: 1377484
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81
pubmed: 26279026
Adv Radiat Oncol. 2020 Mar 20;5(4):527-530
pubmed: 32292837
Bull Math Biol. 2020 Apr 8;82(4):52
pubmed: 32270376
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):597-599
pubmed: 32199941
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur J Cancer. 2014 Nov;50(17):2939-49
pubmed: 25304298
Implement Sci. 2012 Mar 21;7:21
pubmed: 22436067
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
Eur J Cancer. 2007 Jan;43(1):114-21
pubmed: 17084621
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):301-304
pubmed: 32375446
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622